Evidence map›Paper›PMID 29654549›Full record

ArticleJIMD reports2019

Severe Leukoencephalopathy with Clinical Recovery Caused by Recessive BOLA3 Mutations.

C A Stutterd, N J Lake, H Peters, P J Lockhart, R J Taft, M S van der Knaap, A Vanderver, D R Thorburn, C Simons, R J Leventer

Open access · greenAbstract read
In one paragraph

Article in JIMD reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

C A StutterdBruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, VIC, Australia. chloe.stutterd@mcri.edu.au.
N J LakeDepartment of Paediatrics, University of Melbourne, Parkville, VIC, Australia.
H PetersDepartment of Paediatrics, University of Melbourne, Parkville, VIC, Australia.
P J LockhartBruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, VIC, Australia.
R J TaftIllumina Inc, San Diego, CA, USA.
M S van der KnaapDepartment of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands.
A VanderverDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
D R ThorburnVictorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, VIC, Australia.
C SimonsInstitute for Molecular Bioscience, University of Queensland, St Lucia, QLD, Australia.
R J LeventerDepartment of Neurology, Royal Children's Hospital, Parkville, VIC, Australia.
Murdoch Children's Research Institute · AUUniversity of Melbourne · AUAmsterdam UMC Location VUmc · NLChildren's Hospital of Philadelphia · USIllumina (United States) · USUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo identify the genetic aetiology of a distinct leukoencephalopathy causing acute neurological regression in infancy with apparently complete clinical recovery.

methodsWe performed trio whole genome sequencing (WGS) to determine the genetic basis of the disorder. Mitochondrial function analysis in cultured patient fibroblasts was undertaken to confirm the pathogenicity of candidate variants.

resultsThe patient presented at 18 months with acute hemiplegia and cognitive regression without obvious trigger. This was followed by clinical recovery over 4 years. MRI at disease onset revealed bilateral T2 hyperintensity involving the periventricular and deep white matter and MR spectroscopy of frontal white matter demonstrated a lactate doublet. Lactate levels and mitochondrial respiratory chain enzyme activity in muscle, liver and fibroblasts were normal. Plasma glycine was elevated. The MRI abnormalities improved. WGS identified compound heterozygous variants in BOLA3: one previously reported (c.136C>T, p.Arg46*) and one novel variant (c.176G>A, p.Cys59Tyr). Analysis of cultured patient fibroblasts demonstrated deficient pyruvate dehydrogenase (PDH) activity and reduced quantity of protein subunits of mitochondrial complexes I and II, consistent with BOLA3 dysfunction. Previously reported cases of multiple mitochondrial dysfunctions syndrome 2 (MMDS2) with hyperglycinaemia caused by BOLA3 mutations have leukodystrophy with severe, progressive neurological and multisystem disease.

conclusionsWe report a novel phenotype for MMDS2 associated with apparently complete clinical recovery and partial resolution of MRI abnormalities. We have identified a novel disease-causing variant in BOLA3 validated by functional cellular studies. Our patient's clinical course broadens the phenotypic spectrum of MMDS2 and highlights the potential for some genetic leukoencephalopathies to spontaneously improve.

Indexed as

BOLA3Fe–S clusterLeukoencephalopathyMitochondrial diseaseMMDS2Next-generation sequencing

Identifiers

PMID29654549
PMCPMC6323033
OpenAlexW2797562800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.